{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"}],"units":"Participants"}],"groups":[{"description":"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.\n\ntreosulfan: Given IV\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Low dose starting at 2Gy\n\nperipheral blood stem cell transplantation: Given IV per institutional standard practice\n\ntacrolimus: Given IV or PO\n\nallogeneic bone marrow transplantation: Given IV per institutional standard practice\n\nallogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice\n\nmethotrexate: Given IV","id":"OG000","title":"Treatment (Allogeneic Transplantation)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"at 6 months","title":"Incidence of Chronic GVHD","type":"SECONDARY","unitOfMeasure":"Participants"}